Nano Cap New Millennium Growth Fund L P Purchases New Stake in Certara, Inc. $CERT

Nano Cap New Millennium Growth Fund L P purchased a new stake in Certara, Inc. (NASDAQ:CERT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,000 shares of the company’s stock, valued at approximately $1,322,000. Certara makes up approximately 1.1% of Nano Cap New Millennium Growth Fund L P’s portfolio, making the stock its 25th largest position. Nano Cap New Millennium Growth Fund L P owned 0.09% of Certara at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Osaic Holdings Inc. boosted its holdings in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Tower Research Capital LLC TRC grew its stake in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after buying an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in Certara during the 2nd quarter worth $83,000. Curated Wealth Partners LLC bought a new position in Certara during the 4th quarter worth $89,000. Finally, Gamco Investors INC. ET AL bought a new position in Certara during the 4th quarter worth $90,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

CERT opened at $5.17 on Friday. The company has a market capitalization of $804.30 million, a price-to-earnings ratio of -51.70 and a beta of 1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. Certara, Inc. has a 1-year low of $4.45 and a 1-year high of $13.88. The business has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $7.60.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. During the same quarter last year, the company earned $0.14 earnings per share. The business’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Research analysts predict that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CERT shares. Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Stephens dropped their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets dropped their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a research note on Thursday, February 26th. Finally, TD Cowen restated a “buy” rating on shares of Certara in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus target price of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.